

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF “DAPAGLIFLOZIN TABLETS”

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that “Dapagliflozin Tablets” (the “**Product**”) developed by Jiangsu Hansoh Pharmaceutical Group Company Limited* (江蘇豪森藥業集團有限公司), a subsidiary of the Company, has been granted drug registration approval issued by the National Medical Products Administration of the People’s Republic of China.

The Product is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus.

The obtaining of drug registration approval of the Product will further enrich and improve the Group’s product portfolio.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, June 28, 2023

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *for identification purposes only*